Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer (PSROC) and a BRCA mutation (C-PATROL): Overall survival (OS) in predefined subgroups

被引：0
|
作者：
Marme, F. [1 ]
Hilpert, F. [2 ]
Welslau, M. K. [3 ]
Grabowski, J. P. [4 ]
Schneeweiss, A. [5 ]
Hartkopf, A. D. [6 ]
Becker, S. [7 ]
Bauerschlag, D. [8 ]
Fasching, P. A. [9 ]
Brandi, C. [10 ]
Rehbein, J. K. [11 ]
Glowik, R. M. [12 ]
Sehouli, J. [4 ]
机构：
[1] Heidelberg Univ, Univ Med Ctr Mannheim, Med Fac Mannheim, Dept Gynecol Oncol, Mannheim, Germany
[2] Jerusalem Hosp Hamburg, Oncol Ctr, Hamburg, Germany
[3] Klinikum Aschaffenburg, Dept Oncol, Aschaffenburg, Germany
[4] Charite Berlin Univ Med, Dept Gynecol, European Competence Ctr Ovarian Canc, Ctr Oncol Surg, Berlin, Germany
[5] Natl Ctr Tumor Dis NCT, Gynecol Oncol, German Canc Res Ctr, Heidelberg, Germany
[6] Univ Hosp Tubingen, Ctr Womens Hlth, Tubingen, Germany
[7] Goethe Univ Frankfurt, Dept Obstet & Gynecol, Frankfurt, Germany
[8] Univ Klin Jena, Klin & Poliklin Frauenheilkunde & Fortpflanzu, Jena, Germany
[9] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Gynecol & Obstet, Erlangen, Germany
[10] AGAPLESION Markus Hosp, Dept Gynecol, Frankfurt, Germany
[11] Schon Klin Rendsburg, Gynecol & Obstet, Rendsburg, Germany
[12] AstraZeneca GmbH, Med Affairs, Hamburg, Germany
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.842
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
781P
引用
收藏
页码：S586 / S587
页数：2
相关论文
共 50 条
  • [11] NICE guidance on olaparib for maintenance treatment of patients with relapsed, platinum-sensitive, BRCA mutation-positive ovarian cancer
    Tucker, Helen
    Charles, Zoe
    Robertson, Janet
    Adam, Jane
    LANCET ONCOLOGY, 2016, 17 (03): : 277 - 278
  • [12] Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study.
    Pignata, Sandro
    Oza, Amit M.
    Hall, Geoff
    Pardo, Beatriz
    Madry, Radoslaw
    Cibula, David
    Klat, Jaroslav
    Montes, Ana
    Glasspool, Rosalind
    Colombo, Nicoletta
    Pete, Imre
    Herrero, Ana
    Romeo, Marga
    Nedyalkova Ilieva, Rumyana
    Timcheva, Constanta
    Di Maio, Massimo
    Barnicle, Alan
    Taylor, Rosemary
    Bashir, Zahid
    Clamp, Andrew R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [13] Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china
    Shu, Yamin
    Liu, Yanxin
    He, Xucheng
    Ding, Yufeng
    Zhang, Qilin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [14] Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
    Jonathan A Ledermann
    Philipp Harter
    Charlie Gourley
    Michael Friedlander
    Ignace Vergote
    Gordon Rustin
    Clare Scott
    Werner Meier
    Ronnie Shapira-Frommer
    Tamar Safra
    Daniela Matei
    Anitra Fielding
    Bryan Bennett
    David Parry
    Stuart Spencer
    Helen Mann
    Ursula Matulonis
    British Journal of Cancer, 2016, 115 : 1313 - 1320
  • [15] Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
    Ledermann, Jonathan A.
    Harter, Philipp
    Gourley, Charlie
    Friedlander, Michael
    Vergote, Ignace
    Rustin, Gordon
    Scott, Clare
    Meier, Werner
    Shapira-Frommer, Ronnie
    Safra, Tamar
    Matei, Daniela
    Fielding, Anitra
    Bennett, Bryan
    Parry, David
    Spencer, Stuart
    Mann, Helen
    Matulonis, Ursula
    BRITISH JOURNAL OF CANCER, 2016, 115 (11) : 1313 - 1320
  • [16] Olaparib maintenance therapy for platinum-sensitive relapsed ovarian cancer at a single institution: A retrospective study
    Katsuda, Takahiro
    Nishio, Shin
    Tasaki, Shingo
    Park, Jongmyung
    Tasaki, Kazuto
    Tsuda, Naotake
    Ushijima, Kimio
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2024, 50 (07) : 1192 - 1200
  • [17] Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis
    Liu, Ying L.
    Mathews, Cara A.
    Simpkins, Fiona
    Cadoo, Karen A.
    Provencher, Diane
    Mccormick, Colleen C.
    Elnaggar, Adam C.
    Altman, Alon D.
    Gilbert, Lucy
    Black, Destin
    Kabil, Nashwa
    Taylor, Rosie N.
    Barnicle, Alan
    Munley, Jiefen Y.
    Aghajanian, Carol
    CANCER, 2025, 131 (02)
  • [18] Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A single center report
    Skof, Erik
    Stegel, Vida
    Dragos, Vita Setrajcic
    Blatnik, Ana
    Gregoric, Brigita
    Skerl, Petra
    Klancar, Gasper
    Klasinc, Anja Zagozen
    Bombac, Alenka
    Kraje, Mateja
    Novakovic, Srdjan
    GYNECOLOGIC ONCOLOGY, 2024, 190 : 104 - 112
  • [19] Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
    Poveda, A.
    Lheureux, S.
    Colombo, N.
    Cibula, D.
    Lindemann, K.
    Weberpals, J.
    Bjurberg, M.
    Oaknin, A.
    Sikorska, M.
    Gonzalez-Martin, A.
    Madry, R.
    Perez, M. J. Rubio
    Ledermann, J.
    Davidson, R.
    Blakeley, C.
    Bennett, J.
    Barnicle, A.
    Skof, E.
    GYNECOLOGIC ONCOLOGY, 2022, 164 (03) : 498 - 504
  • [20] Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
    Poveda, Andres
    Floquet, Anne
    Ledermann, Jonathan A.
    Asher, Rebecca
    Penson, Richard T.
    Oza, Amit M.
    Korach, Jacob
    Huzarski, Tomasz
    Pignata, Sandro
    Friedlander, Michael
    Baldoni, Alessandra
    Park-Simon, Tjoung-Won
    Sonke, Gabe S.
    Lisyanskaya, Alla Sergeevna
    Kim, Jae-Hoon
    Abdo Filho, Elias
    Vergote, Ignace
    Rowe, Phil
    Pujade-Lauraine, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345